References
- Zhang X , HuangY, ShiX. Emerging roles of lysine methylation on non-histone proteins. Cell. Mol. Life Sci.72(22), 4257–4272 (2015).
- Fu W , LiuN, QiaoQet al. Structural basis for substrate preference of SMYD3, a SET domain-containing protein lysine methyltransferase. J. Bio. Chem.291(17), 9173–9180 (2016).
- Spellmon N , HolcombJ, TrescottL, SirinupongN, YangZ. Structure and function of SET and MYND domain-containing proteins. Int. J. Mol. Sci.16, 1406–1428 (2015).
- Mazur PK , GozaniO, SageJ, ReynoirdN. Novel insights into the oncogenic function of the SMYD3 lysine methyltransferase. Transl. Cancer Res.5(3), 330–333 (2016).
- Nagandla H , LopezS, YuWet al. Defective myogenesis in the absence of the muscle-specific lysine methyltransferase SMYD1. Dev. Biol.410(1), 86–97 (2016).
- Ohtomo-Oda R , KomatsuS, MoriTet al. SMYD2 overexpression is associated with tumor cell proliferation and a worse outcome in human papillomavirus – unrelated nonmultiple head and neck carcinomas. Hum. Pathol.49, 145–155 (2016).
- Huang L , XuAM. SET and MYND domain containing protein 3 in cancer. Am. J. Transl. Res.9(1), 1–14 (2017).
- Michalak EM , VisvaderJE. Dysregulation of histone methyltransferases in breast cancer – opportunities for new targeted therapies?Mol. Oncol.10(10), 1497–1515 (2016).
- Mazur P , ReynoirdN, KhatriPet al. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature510, 283–287 (2014).
- Osherovich L , WriterS. Putting SMYD3 on the map. SciBX7(23), 664 (2014).
- Dhillon A , HaganS, RathO, KolchW. MAP kinase signalling pathways in cancer. Oncogene26, 3279–3290 (2007).
- Van Aller Glenn S , GravesAlan P, ElkinsPatricia Aet al. Structure-based design of a novel SMYD3 inhibitor that bridges the SAM-and MEKK2-binding pockets. Structure24(5), 774–781 (2016).
- Mitchell L , Boriack-SjodinP, SmithSet al. Novel oxindole sulfonamides and sulfamides: EPZ031686, the first orally bioavailable small molecule SMYD3 inhibitor. ACS Med. Chem. Lett.7(2), 134–138 (2016).
- Peserico A , GermaniA, SanesePet al. A SMYD3 small-molecule inhibitor impairing cancer cell growth. J. Cell. Physiol.230(10), 2447–2460 (2015).
- Wu G , RobertsonDH, BrooksCL, ViethM. Detailed analysis of grid-based molecular docking: a case study of CDOCKER – a CHARMm-based MD docking alogrithm. J. Comput. Chem.24(13), 1549–1562 (2003).
- Sirinupong N , BrunzelleJ, DokoE, YangZ. Structural insights autoinhibtion and posttranslational activation of histone methyltransferase SMYD3. J. Mol. Biol.406(1), 149–159 (2011).
- Böhm HJ . LUDI: rule-based automatic design of new substituents for enzyme ihibitor leads. J. Comput. Aided Mol. Des.6(6), 593–606 (1992).
- Rogers D , HopfingerAJ. Application of genetic function approximation to quatntitative structure-activity relationships and quantitative structure-property relationships. J. Chem. Inf. Comput. Sci.34(4), 854–866 (1994).
- Rajajeyabalachandran G , KumarS, MurugesanTet al. Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents. Expert Opin. Ther. Targets21(2), 145–157 (2017).
- Sheng-You H , SamZG, XiaoqinZ. Scoring functions and their evaluation methods for protein-ligand docking: recent advances and future directions. Phys. Chem. Chem. Phys.12, 12899–12908 (2010).